Meningococcal group A, C, Y and W-135 conjugate vaccine.
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.